SCHEMBL1318629

SCHEMBL1318629

Nc1nc2ccc(F)cn2c1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT1 P31749 2/20 0.53
▸ AKT2 P31751 2/20 0.53
▸ PIK3CD O00329 5/20 0.49
▸ PIK3R1 P27986 5/20 0.49
▸ PIK3CB P42338 5/20 0.49
▸ PIK3CG P48736 5/20 0.49
▸ USP7 Q93009 4/20 0.49
▸ CYP11B1 P15538 3/20 0.42
▸ CYP11B2 P19099 3/20 0.42
▸ ALDH1A3 P47895 1/20 0.41
▸ FGFR1 P11362 2/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ IGF1R P08069 1/20 0.39
▸ LTK P29376 1/20 0.39
▸ MAP2K2 P36507 1/20 0.39
▸ MAPK9 P45984 1/20 0.39
▸ RPS6KA3 P51812 1/20 0.39
▸ PRKX P51817 1/20 0.39
▸ PRKCQ Q04759 1/20 0.39
▸ TNK2 Q07912 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7682754 0.82 CDK2 (0.58) AKT1AKT2CDK2CDK4
SCHEMBL1321272 0.81 USP7 (0.43) AKT1AKT2PIK3CDPIK3R1PIK3CB
SCHEMBL7680211 0.79 CDK2 (0.60) AKT1AKT2USP7CDK2CDK4
SCHEMBL2504442 0.78 PIK3CD (0.55) AKT1AKT2PIK3CDPIK3R1PIK3CB
SCHEMBL2549015 0.78 AKT1 (0.48) AKT1AKT2PIK3CDPIK3R1PIK3CB
SCHEMBL15730473 0.77 AKT1 (0.56) AKT1AKT2CYP11B1CYP11B2ALDH1A3
SCHEMBL12196845 0.77 PIK3CD (0.54) AKT1AKT2PIK3CDPIK3R1PIK3CB
SCHEMBL7467961 0.77 AKT1 (0.56) AKT1AKT2USP7CDK2CDK4
Hydrochloric Acid SCHEMBL18128834 0.76 AKT1 (0.55) AKT1AKT2CYP11B1CYP11B2ALDH1A3
SCHEMBL19048703 0.76 USP7 (0.76) AKT1AKT2USP7NTRK1LTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018208-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2015-04-28 — — US disclosed
US-9018208-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2015-04-28 — — US disclosed
US-9018208-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2015-04-28 — — US disclosed
US-20130143889-A1 Heterocycles As Potassium Channel Modulators ICAGEN INC. (US) 2013-06-06 — — US disclosed
US-20130143889-A1 Heterocycles As Potassium Channel Modulators ICAGEN INC. (US) 2013-06-06 — — US disclosed
US-20130143889-A1 Heterocycles As Potassium Channel Modulators ICAGEN INC. (US) 2013-06-06 — — US disclosed
US-8431608-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2013-04-30 — — US disclosed
US-8431608-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2013-04-30 — — US disclosed
US-8431608-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2013-04-30 — — US disclosed
EP-2536718-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2012-12-26 — — EP disclosed
WO-2011102964-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2011-08-25 — — WO disclosed
WO-2011102964-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2011-08-25 — — WO disclosed
US-20100240663-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-09-23 — — US disclosed
US-20100240663-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-09-23 — — US disclosed
US-20100240663-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-09-23 — — US disclosed
EP-2178373-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2010-04-28 — — EP disclosed
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-03-05 — — US disclosed
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-03-05 — — US disclosed
WO-2009026254-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-02-26 — — WO disclosed
WO-2009026254-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143889-A1 Heterocycles As Potassium Channel Modulators KCNK10, KCNK9, KCNJ2 AKT1 2512/4885AKT2 2852/4885PIK3CD 1436/4885
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK2, KCNK17 AKT1 2265/4885AKT2 2416/4885PIK3CD 1435/4885
US-20100240663-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK2, KCNK17 AKT1 2265/4885AKT2 2416/4885PIK3CD 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback